Tumor PD-L1 expression generally correlates with improved efficacy with anti-PD-1/PD-L1 ICIs in R/M HNSCC, with increased predictive value when including PD-L1 expression on tumor infiltrating immune cells. Here, PDCD1 is linked to head and neck squamous cell carcinoma.